PRPO · NASDAQ
Healthcare · Diagnostics & Research
$19.35
+3.59%
Close on Oct 29, 2026
Research data through 2026-10-29
Long-term research evidence only. No price targets, no trading signals, no recommendations.
Free research · no account required
Research data through Oct 29, 2026. Research is updated periodically, not in real time.
51
of 100 · stored research reading
Stored Quality research reads 51 of 100, a middle-of-the-universe reading. The measurements behind it are mixed.
Quality research measures durability of the business itself from stored fundamentals: balance-sheet strength, profitability consistency and cash generation. It is a research reading, not a prediction of future returns.
How this is measured83
of 100 · stored research reading
Stored Fundamental Momentum research reads 83 of 100. Stored measurements classify recent reported fundamentals as accelerating. This describes reported financial change already disclosed, with no forward-looking claim.
Fundamental Momentum research measures the direction of recently reported company fundamentals compared with the company's own history. It describes reported change, not future price movement.
How this is measured5
of 100 · stored research reading
Stored Capital Returns research reads 5 of 100, recorded as weak. No dividend is recorded for this company, so the reading rests on buybacks and dilution control. Share count has increased at about 11.2% a year in the stored window.
Capital Returns research measures how a company has actually returned cash to shareholders: dividend record, buyback effectiveness, dilution control and how those payments were funded.
How this is measuredNot currently available. No stored valuation ratios exist for this company.
Learn the basics of valuationInvestor intelligence
The research below is part of Investor membership. Values are withheld from this page entirely — nothing premium is loaded into it. Start the free trial and the intelligence you asked for unlocks right here.
Investor
Unlock its Pro Investor Score and ranking across the research universe.
7 days · No credit card required
Investor
Unlock Risk Intelligence, Price Risk, and Market Confirmation.
7 days · No credit card required
Investor
Unlock the Pro Research Brief with What Changed & Why, research history and tensions.
7 days · No credit card required
Investor
Unlock Pro Investor Intelligence: disclosed professional-manager and insider activity beside company research.
7 days · No credit card required
Investor
Unlock Pro Investor AI to ask questions grounded in Pro Investor Academy research and evidence.
7 days · No credit card required
Investor
Save companies and monitor how their research changes over time.
7 days · No credit card required
Explore other companies in this industry. These are objective industry neighbours, not suggested alternatives.
Pro Investor Academy continuously applies its research rules across the eligible universe and surfaces a small number of investments for deeper research when they qualify.
Research Collections
This company does not currently satisfy any collection rule. That is a stored research result, not a judgement about the business.
Browse collectionsPlain-English definitions, with the formula and the limitations of each measure.
In the company’s own words
We are a healthcare biotechnology company with a mission to battle the systemic problem of disease misdiagnosis, by focusing on improving cancer diagnostics, particularly, hematologic malignancies. Our objective is to enhance diagnostic accuracy and accessibility while building a sustainable business model that supports ongoing innovation. We aim to achieve this through a combination of clinical laboratory services and proprietary diagnostic product development. By integrating diagnostic services with product development, our service business doubles as a self-funded research and development ("R&D") unit, enabling us to achieve rapid and cost-efficient innovation rather than being a major cost center for us.
This unique integrated operating structure is the foundation of our approach to research, development, and product commercialization. Unlike other companies that rely primarily on stand-alone research facilities or external clinical validation programs, our clinical laboratory operations enables our R&D team to evaluate, refine, and validate diagnostic products in the course of routine clinical testing activities, and at incremental cost. Through these activities, we generate clinical data, operational experience, and specimen access that support ongoing assay development and product improvement. While these activities are initially conducted to provide diagnostic services to patients and their healthcare providers, they also contribute to product development and validation processes.
We have a single operating segment but operate two business divisions that are complementary to each other:
Our pathology services division provides specialized cancer diagnostic testing services to physicians, hospitals, and laboratories. This division generates revenue and supports the development of our expertise in oncology diagnostics.
Quoted from the business section of this company’s 10-K filed March 30, 2026. Read the filing
General research only. Not personalized advice. Public filings may be delayed, amended, incomplete, or reflect positions that have changed since the reporting date.
